Machine-learning techniques, statistical imputation, and natural language processing give more accurate forecasts of clinical trial outcomes, durations, probabilities of approval, and financial performance
By managing risk through systematic portfolio construction methods, all biopharma stakeholders can lower the cost of capital and improve risk-adjusted returns, bringing more capital into this important sector
Better financing structures and business decisions will help bring more therapies to patients faster and, ultimately, cheaper
Strategies will focus on public and private companies developing potentially life-changing medical treatments Partnership combines the insights and scale of BlackRock’s active investment platform with QLS’s cutting-edge approach to investing in life sciences NEW YORK,...
BIO, QLS, and Informa Pharma Intelligence have released a new report on clinical development success rates covering 2011-2020
The report includes comparisons of success rates across indications and modalities, regulatory factors, and predictive factors driving successes and failures in drug development. This new data will help shape risk profiles and valuation metrics across investment and...
Partnership will help inform key decisions with new drug-level probability of approval scores powered by QLS and incorporated into Informa Pharma Intelligence’s Biomedtracker
Ask a Question
Want to know more? Send us a message!